Pull to refresh
Logo
What Changed
Following Why Sign Up
Abbott wins FDA approval for patient-facing heart failure monitoring app

Abbott wins FDA approval for patient-facing heart failure monitoring app

New Capabilities

The FDA cleared an app that lets CardioMEMS patients see their pulmonary artery pressure and get medication instructions from their care teams; Abbott plans to roll it out later in 2026

October 9th, 2026: CardioGuide app and Dynamic Treatment Plan debut at HFSA 2026

Overview

Updated Oct 25

Heart failure patients with Abbott's implanted pressure sensor will be able to see their own readings on a smartphone. The FDA approved the update on Oct. 5, 2026, and Abbott says the CardioGuide HF App will reach U.S. patients later in 2026.

Abbott showed the app and a companion tool, the Dynamic Treatment Plan, at the Heart Failure Society of America meeting in October. The treatment plan lets clinicians send medication instructions through the app; patients are not expected to change their own drugs based on the numbers.

Why it matters

Patients who see their own pressure trends could catch worsening heart failure weeks before symptoms, potentially avoiding hospitalizations.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

12 years
Years since CardioMEMS first FDA approval
The system was first approved in 2014; this update adds patient-facing capabilities.
$8.2B
Heart failure monitoring market size (2025)
Projected to reach $15.82B by 2034, according to market analysis cited by EveryTicker.
$19B
Abbott Medical Devices annual revenue (2024)
About 45% of Abbott's total company sales, with CardioMEMS contributing to that growth.
$401M
Abbott heart failure sales, Q2 2026
Worldwide heart failure sales rose 9% from a year earlier, with U.S. sales up 10.9%, PharmaDeviceNews reported.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Andrew J. Sauer, M.D.
Andrew J. Sauer, M.D.
Cardiologist and vice president for research at Saint Luke's Mid America Heart Institute
Professor of medicine at the University of Missouri-Kansas City

Organizations Involved

Abbott
Abbott
Medical devices and diagnostics company
Developer of the CardioMEMS HF System

Global healthcare company headquartered in Abbott Park, Illinois, that develops the CardioMEMS HF System.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulator
Approved the CardioMEMS patient-facing app update

The federal agency that regulates medical devices and drugs in the United States.
Medtronic plc
Medtronic plc
Healthcare technology company
Competitor in remote heart failure monitoring

Offers competing remote monitoring solutions for heart failure patients.
Boston Scientific
Boston Scientific
Medical device manufacturer
Competitor in remote heart failure monitoring

Offers competing remote monitoring solutions for heart failure patients.

Timeline

2014 October 2026

7 events Latest: October 9th, 2026 · 1 month ago
Tap a bar to jump to that date

  1. CardioGuide app and Dynamic Treatment Plan debut at HFSA 2026

    Latest Product

    Abbott displayed the CardioGuide HF App and Dynamic Treatment Plan in the exhibit hall at the Heart Failure Society of America's 2026 annual meeting.

  2. FDA approves patient-facing app capabilities

    Regulatory

    The FDA approves updates to the CardioMEMS HF System that let patients view pulmonary artery pressure readings on smartphones and receive medication adjustment instructions.

  3. CardioMEMS HERO reader commercial launch

    Product

    Abbott launched the HERO external data recorder for CardioMEMS, about the size of a laptop case, with Wi-Fi and cellular connectivity for taking readings.

  4. FDA approves CardioMEMS HERO reader

    Product

    The FDA approves Abbott's next-generation HERO reader for CardioMEMS patients. The device is 60% lighter than the previous model, takes a reading in under 60 seconds, and is the only patient reader with integrated Wi-Fi and cellular connectivity. U.S. commercial release was to begin soon after.

  5. CMS issues national coverage determination for CardioMEMS

    Regulatory

    The Centers for Medicare and Medicaid Services issued a national coverage determination for CardioMEMS.

  6. FDA expands CardioMEMS approval to NYHA Class II patients

    Regulatory

    The FDA broadens CardioMEMS approval to include earlier-stage heart failure patients.

  7. FDA first approves CardioMEMS HF System

    Regulatory

    The FDA approves Abbott's CardioMEMS HF System, a sensor implanted in the pulmonary artery that measures pressure for heart failure management.

Scenarios

1

CardioMEMS patient app drives measurable drop in heart failure readmissions

Possible Resolves by Oct 5, 2027

Discussed by: Abbott and clinical researchers

Clinicians enable the patient-facing features widely. Patients who see their pressure trends and receive medication adjustment instructions catch decompensation earlier, reducing hospitalizations. Abbott reports adoption and outcomes data in coming quarters.

2

Clinicians slow to enable CardioMEMS patient app amid workflow concerns

Possible Resolves by Oct 5, 2027

Discussed by: AllMind AI market analysis

Care teams worry that more patient-facing readings and medication changes increase staff workload. Clinician activation lags, and the feature sees limited adoption despite FDA approval.

3

Medtronic or Boston Scientific matches Abbott with patient-facing remote monitoring

Possible Resolves by Oct 5, 2027

Discussed by: EveryTicker market analysis

Competitors respond with similar patient-facing features in their remote monitoring platforms, raising the bar for the whole category. Abbott's differentiation narrows.

4

Patients ask about rising pressure numbers their care team hasn't acted on yet

Possible Resolves by Q2 2027

Discussed by: PharmaDeviceNews

The app shows raw pressure readings and trends. PharmaDeviceNews wrote that patient-facing data helps when it comes with a clear clinical plan and is less useful when it doesn't. If a patient sees a climb before the care team responds, clinics could field more calls between visits.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2017

FreeStyle Libre brings glucose monitoring to patients (2017)

Abbott launched the FreeStyle Libre continuous glucose monitor, which let diabetes patients see their glucose readings in real time on a reader or smartphone. Earlier CGMs required clinician interpretation; the Libre was designed for direct patient use.

Then

The Libre became one of Abbott's fastest-growing products and transformed diabetes management.

Now

It established patient-facing continuous monitoring as a viable model for chronic disease care.

Why this matters now

Abbott is applying the same patient-facing playbook to heart failure monitoring with the CardioMEMS app.

2010s

Patient portals open medical records to patients (2010s)

Hospitals began giving patients online access to their medical records, lab results, and clinician notes through patient portals. The OpenNotes movement pushed for transparency in clinical documentation.

Then

Patients gained direct access to their health data for the first time.

Now

It normalized the idea that patients should see their own clinical data, setting the stage for device data to go patient-facing.

Why this matters now

The CardioMEMS app extends this transparency trend to implantable device data.

Sources

(14)
+8
PR Newswire StockTitan EveryTicker AllMind AI MarketScreener Medical Device News Magazine TradingView Securities.io MassDevice MedTech Dive Abbott PharmaDeviceNews Heart Failure Society of America LinkedIn